Research use only. This compound is supplied for in-vitro laboratory research by qualified researchers. It is not for human or veterinary consumption and has not been evaluated by the FDA.
Matrix & Cytoskeletal
BPC/TB Stack
Certificate pending · 10mg
10mg$79.99each
Certificate pending for the 10mg lot.The signed report will be published here as soon as the laboratory returns it.
Vial strength
Ordering at volume or on a schedule?
Request a supply quote →Buy more of this strength and the price comes down. The store applies it at checkout - there is nothing to enter.
Free US shipping - no minimum
Tell us the Report ID or Laboratory ID shown on the certificate, and what you observed. If independent testing shows a discrepancy against our published certificate, we refund the lot in full and pull it from sale pending investigation.
Tell us the Report ID or Laboratory ID shown on the certificate, and what you observed. If independent testing shows a discrepancy against our published certificate, we refund the lot in full and pull it from sale pending investigation.
Certificate pending
Discreet packaging
Dispatched within one business day
Free US shipping, no minimum
In stock, ships from our US fulfilment partner
Compound information
- Type
- Matrix & Cytoskeletal
- Sequence
- Blend: BPC-157 and TB-500
- Form
- Lyophilized powder blend
- Vial strength
- 10mg
- Catalogue number
- PX-BPCTB-10MG
- Purity
- Certificate pending for this strength
Identifiers are published properties of the molecule. Values we cannot confirm are omitted rather than estimated.
BPC/TB Stack is a blend rather than a single compound: BPC-157 and TB-500 supplied together in one vial. Because it is a mixture it has no single CAS number, molecular formula or molecular weight, and any listing that gives it one is describing something else.
The two components are chemically unrelated and act on different molecular systems, which is the substantive reason they are catalogued together rather than a claim about the combination. BPC-157 is a fifteen-residue free-acid peptide derived from a protein of human gastric juice, and the signalling reported for it centres on VEGFR2, Akt and eNOS in endothelial culture and on focal adhesion kinase and paxillin phosphorylation in fibroblast culture. TB-500 is a seven-residue N-acetylated fragment of thymosin beta-4 whose described interaction is with monomeric actin inside the cell, through the LKKTET motif, and for which no cell-surface receptor has been identified.
No published study characterises this two-component mixture as an entity. Citations shown on this page are papers about the individual components, and the site labels them as such; nothing here should be read as research into the combination.
Handling is governed by the more fragile component rather than by an average. Neither peptide contains cysteine, methionine or tryptophan, so the vial carries no oxidation-prone side chain, and neither has an aromatic chromophore, so neither component can be quantified by absorbance at 280 nm and a separation-based method is required to resolve them. The documented degradation route for the TB-500 component is exopeptidase truncation to shorter acetylated fragments, and the documented behaviour of the BPC-157 component in plasma is rapid breakdown to short fragments; a mixture held in any matrix with peptidase activity will therefore change composition, not merely concentration.
Because the vial label states a combined mass rather than a mass per component, a price or concentration expressed per milligram is not comparable with the same figure for a single compound. The site deliberately does not publish a per-milligram rate for blends for that reason.
Background
The BPC/TB Stack is a two-component blend, BPC-157 and TB-500 in one vial, so it has no single CAS number, formula or molecular weight. The components are chemically unrelated: BPC-157 is a fifteen-residue free-acid peptide from a gastric-juice protein, with reported signalling through VEGFR2, Akt and eNOS in endothelial culture, while TB-500 is a seven-residue N-acetylated fragment of thymosin beta-4 that interacts with monomeric actin through its LKKTET motif. No published study characterises the mixture itself as an entity.
Research applications
Where this compound appears in the published literature. Each area points to the papers listed under Primary literature below. These describe what was studied, not an application of this product.
Specifications
- Supplied as
- Lyophilized powder blend
- Available strengths
- 10mg · 20mg
- Components
- BPC-157 · TB-500
- Storage
- Store lyophilized at -20C, protected from light and moisture.
- Intended use
- In-vitro laboratory research only
Primary literature
Peer-reviewed papers indexed on PubMed that study this compound. We did not write them and we do not summarise them — each reference opens the record on PubMed so you can read the work itself. Publication is not evidence of safety or efficacy, and none of this research was conducted by PepXtide.
This product is several peptides in one vial. The papers below study those peptides individually — none of them is research into this combination.
- Pharmaceuticals (Basel), 2025 · PMID 40005999
- HSS J, 2025 · PMID 40756949
- Curr Rev Musculoskelet Med, 2025 · PMID 40789979
- Front Pharmacol, 2021 · PMID 34267654
- Cell Tissue Res, 2019 · PMID 30915550
PubMed, PubChem and ClinicalTrials.gov are independent scientific databases. A record or a published paper is not an endorsement of this product, and nothing indexed there describes an application, dose or outcome supported by PepXtide.
Storage & handling
Lyophilized
Store lyophilized at -20C, protected from light and moisture. Neither component carries an oxidation-prone side chain, and the documented degradation routes for both are peptidase truncation rather than chemical breakdown, so the two components can shift in relative proportion rather than simply in concentration.
Reconstituted
Once reconstituted, keep refrigerated and use within the working period established by the laboratory.
Handling notes
- Store lyophilized at -20C, protected from light and moisture.
- Neither component contains cysteine, methionine or tryptophan, so the vial carries no oxidation-prone side chain.
- Both components degrade by peptidase truncation, so in any matrix with peptidase activity the mixture changes composition, not merely concentration.
- Neither component absorbs usefully at 280 nm; a separation-based method is needed to resolve and quantify them.
- Once reconstituted, keep refrigerated and use within the working period established by the laboratory.
Safety & handling
Bench handling, not a dosing guide.
Intended use
Supplied strictly as a laboratory research material for in-vitro study by qualified researchers. Not for human or veterinary use, not for ingestion or injection, and not for any clinical or diagnostic application.
Personal protective equipment
Handle with gloves, eye protection and a laboratory coat. Weigh and transfer lyophilized powder in a ventilated enclosure to avoid generating an inhalable dust.
Reconstitution
Reconstitute against the diluent and volume appropriate to your protocol, adding solvent slowly down the vial wall rather than directly onto the pellet. Do not shake. This is a handling note, not a dosing guide.
Storage after opening
Once reconstituted, refrigerate and use within the period appropriate to the material. Avoid repeated freeze-thaw cycles, which degrade peptides faster than continuous storage at the listed temperature.
Disposal
Dispose of material and containers in accordance with your institution's chemical waste procedures and applicable local regulations.
Related compounds
Matrix & Cytoskeletal
BPC-157
Lyophilized powder
Matrix & Cytoskeletal
TB-500
Lyophilized powder
Matrix & Cytoskeletal
KPV
Lyophilized powder
Solutions & Supplies
Reconstitution Water
Sterile solution
Research notice
Specifications and the structural model for each component are on its own product page. Supplied as a lyophilized powder for in-vitro laboratory research only. No statement on this page describes an application, benefit, dose, route or outcome. Descriptions are structural and mechanistic, and reference data such as CAS numbers and molecular formulas is published information about the compound itself, provided for identification. No measured result is shown for this strength because a certificate has not yet been published for its lot.